Targeting interleukin-22 for cancer therapy.
Anamarija Markota, Stefan Endres, Sebastian Kobold
https://pubmed.ncbi.nlm.nih.gov/29617184/Actively Recruiting
Led by Xingchen Peng · Updated on 2025-12-29
6
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to investigate the safety, tolerability, and preliminary anti-tumor activity of the IL-22BPLNP compound in patients with refractory malignant solid tumors. These tumors include advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, and malignant melanoma. The study focuses on patients who have failed second-line treatments or have advanced recurrence or metastatic disease, addressing a serious health challenge with limited current treatment options. Participants will receive the IL-22BPLNP compound through intratumoral injections. Six patients are divided into two dose groups, receiving either 25 micrograms or 50 micrograms of the compound. The treatment involves five doses four weekly doses followed by a fifth dose one month after the fourth. This basic immunization phase lasts about two months, with personalized treatment following. During the study, participants will be closely monitored for safety and treatment response. Researchers will assess dose-limiting toxicities and interruptions due to adverse events. They will also measure tumor response rates, disease control, remission times, progression-free survival, and overall survival. The observation period for some outcomes extends up to 36 months, ensuring thorough evaluation of the compounds effects and safety throughout and after treatment.
CONDITIONS
A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity
X
Xingchen Peng
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Xingchen Peng
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 2 months
Participants receive intratumoral injections of the IL-22BP/LNP compound according to their assigned dose group. The basic immunization includes 5 doses: the first 4 doses are given weekly, and the 5th dose is administered 1 month after the 4th dose. The entire treatment period lasts approximately 2 months.
5 visits for injections over 2 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Anamarija Markota, Stefan Endres, Sebastian Kobold
https://pubmed.ncbi.nlm.nih.gov/29617184/Xucheng Hou, Tal Zaks, Robert Langer...
https://pubmed.ncbi.nlm.nih.gov/34394960/Omer Gersten, Magali Barbieri
https://pubmed.ncbi.nlm.nih.gov/33843999/Jan Kempski, Anastasios D Giannou, Kristoffer Riecken...
https://pubmed.ncbi.nlm.nih.gov/32585307/Seyed Hossein Kiaie, Naime Majidi Zolbanin, Armin Ahmadi...
https://pubmed.ncbi.nlm.nih.gov/35701851/Nilofer Sayed, Prince Allawadhi, Amit Khurana...
https://pubmed.ncbi.nlm.nih.gov/35123997/Ana Melissa Ccopa Ibarra, Rebeca Boltes Cecatto, Lara Jansiski Motta...
https://pubmed.ncbi.nlm.nih.gov/34855034/Hyuna Sung, Jacques Ferlay, Rebecca L Siegel...
https://pubmed.ncbi.nlm.nih.gov/33538338/Babak Arjmand, Bagher Larijani, Motahareh Sheikh Hosseini...
https://pubmed.ncbi.nlm.nih.gov/31845133/Xingchen Peng
Lead Sponsor